Oil rich in carotenoids instead of vitamins C and E as a better option to reduce doxorubicin-induced damage to normal cells of Ehrlich tumor-bearing mice: Hematological, toxicological and histopathological evaluations

Journal of Nutritional Biochemistry

Volumn 25, Issue 11, 2014, Pages 1161-1176

  Miranda Vilela, Ana Luisa ^a,b   Grisolia, Cesar K ^a   Longo, João Paulo F ^a   Peixoto, Raphael C A ^a   de Almeida, Marcos Célio ^a   Barbosa, Lilian Carla P ^a   Roll, Mariana M ^a   Portilho, Flávia A ^a   Estevanato, Luciana L C ^a   Bocca, Anamélia L ^a   Báo, SÔnia N ^a   Lacava, Zulmira G M ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b Scientific Initiation Scholarship FAPESP   (Brazil)

Author keywords

Animal model; Breast cancer; Chemotherapy; Doxorubicin induced damage; Pequi oil (Caryocar brasiliense)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CAROTENOID; CREATININE; DOXORUBICIN; GAMMA GLUTAMYLTRANSFERASE; OIL; PEQUI OIL; UNCLASSIFIED DRUG; UREA; ANTINEOPLASTIC ANTIBIOTIC; VEGETABLE OIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARDIOTOXICITY; CARYOCAR BRASILIENSE; CELL DAMAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA DAMAGE; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; FEMALE; FRUIT; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MORPHOMETRICS; MOUSE; NEPHROTOXICITY; NONHUMAN; SUPPLEMENTATION; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; UREA BLOOD LEVEL; ANIMAL; CARCINOMA, EHRLICH TUMOR; CHEMISTRY; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ASCORBIC ACID; CARCINOMA, EHRLICH TUMOR; CAROTENOIDS; DOXORUBICIN; FEMALE; MICE; OXIDATIVE STRESS; PLANT OILS; VITAMIN E;

EID: 84908239764     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.06.005     Document Type: Article

References (62)

1. Brufman G., Colajori E., Ghilezan N., Lassus M., Martoni M., Perevodchikova N., et al. Doubling epirubicin dose intensity (100mg/m2 versus 50mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 1997, 8:155-162.
2. Ingvarsson S. Breast cancer: introduction. Semin Cancer Biol 2001, 11:323-326.
3. Key T.J., Verkasalo P.K., Banks E. Epidemiology of breast cancer. Lancet Oncol 2001, 2:133-140.
4. McPherson K., Steel C., Dixon J. ABC of breast diseases: breast cancer - epidemiology, risk factors, and genetics. BMJ 2000, 321:624-628.
5. Irvin J.R.W., Muss H.B., Mayer D.K. Symptom management in metastatic breast cancer. Oncologist 2011, 16:1203-1214.
6. Verrill M. Chemotherapy for early-stage breast cancer: a brief history. Br J Cancer 2009, 101:S2-S5.
7. Dhankhar R., Vyas S.P., Jain A.K., Arora S., Rath G., Goyal A.K. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol 2010, 38:230-249.
8. World Health Organization (WHO). Breast Cancer Awareness Month in October, 2014.
9. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011, 11:135-141.
10. Ibrahim S.S., Barakat M.A., Helmy H.T.S. Modulating effect of carvedilol on doxorubicin-induced cardiomyopathy and hepatic damage. J Am Sci 2010, 6:20-32.
11. Hofland K.F., Thougaard A.V., Sehested M., Jensen P.B. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 2005, 11:3915-3924.
12. Xu X., Persson H.L., Richardson D.R. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005, 68:261-271.
13. Quiles J.L., Huertas J.R., Battino M., Mataix J., Ramírez-Tortosa M.C. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002, 180:79-95.
14. Santos H.S., Cruz W.M.S. A terapia nutricional com vitaminas antioxidantes e o tratamento quimioterápico oncológico. Rev Bras Cancerol 2001, 47:303-308.
15. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007, 96:2181-2196.
16. Akbas H.S., Timur M., Ozben T. Concurrent use of antioxidants in cancer therapy: an update. Expert Rev Clin Immunol 2006, 2:931-939.
17. González M.J., Miranda-Massari J.R., Mora E.M., Guzmán A., Riordan N.H., Riordan H.D., et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther 2005, 4:32-44.
18. Gonzalez M.J., Miranda-Massari J.R. Advances in vitamin C research. Integr Cancer Ther 2006, 5:7-8.
19. Borek C. Dietary antioxidants and human cancer. Integr Cancer Ther 2004, 3:333-341.
20. Moss R.W. Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?. Integr Cancer Ther 2006, 5:63-82.
21. Borek C. Antioxidants and radiation therapy. J Nutr 2004, 134:3207S-3209S.
22. Miranda-Vilela A.L., Portilho F.A., de Araujo V.G., Estevanato L.L., Mezzomo B.P., Almeida Santos M.F., et al. The protective effects of nutritional antioxidant therapy on Ehrlich solid tumor-bearing mice depend on the type of antioxidant therapy chosen: histology, genotoxicity and hematology evaluations. J Nutr Biochem 2011, 22:1091-1098.
23. Miranda-Vilela A.L., Peixoto R.C.A., Longo J.P.F., Cintra D.O.S., Portilho F.A., Miranda K.L.C., et al. Dextran-functionalized magnetic fluid mediating magnetohyperthermia combined with preventive antioxidant pequi-oil supplementation: potential Use against cancer. J Biomed Nanotechnol 2013, 9:1261-1271.
24. Miranda-Vilela A.L., Grisolia C.K., Resck I.S., Mendonça M.A. Characterization of the major nutritional components of Caryocar brasiliense fruit pulp by nmr spectroscopy. Quim Nova 2009, 32:2310-2313.
25. Higby W.K. A simplified method for determination of some aspects of the carotenoid distribution in natural and carotene-fortified orange juice. J Food Sci 1962, 27:42-49.
26. Brand-Williams W., Cuvelier M.E., Berset C. Use of a free radical method to evaluate antioxidant activity. LWT - Food Sci Technol 1995, 28:25-30.
27. Razali N., Razab R., Junit S.M., Aziz A.A. Radical scavenging and reducing properties of extracts of cashew shoots (Anacardium occidentale). Food Chem 2008, 111:38-44.
28. Atmani D., Chaher N., Berboucha M., Ayouni K., Lounis H., Boudaoud H., et al. Antioxidant capacity and phenol content of selected Algerian medicinal plants. Food Chem 2009, 112:303-309.
29. Swain T., Hillis W.E. The phenolic constituents of Prunus domestica. I. - The quantitative analysis of phenolic constituents. J Sci Food Agric 1959, 10:63-68.
30. AVMA AVMA guidelines on euthanasia 2007.
31. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
32. Yanase M., Shinkai M., Honda H., Wakabayashi T., Yoshida J., Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: ex vivo study. Cancer Sci 1997, 88:630-632.
33. Carneiro M.L.B., Peixoto R.C.A., Joanitti G.A., Oliveira R.G.S., Telles L., Miranda-Vilela A.L., et al. Antitumor effect and toxicity of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles in mice bearing breast cancer. J Nanotechnol 2013, 11:4.
34. Lazăr D., Tăban S., Sporea I., Dema A., Cornianu M., Lazăr E., et al. Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol 2010, 51:655-661.
35. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006, 291:H1273-H1280.
36. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184-191.
37. Collins A., Ai-guo M., Duthie S. The kinetics of repair of oxidative DNA damage (strand breaks and oxidised pyrimidines) in human cells. Mutat Res 1995, 336:69-77.
38. Jaloszynski P., Kujawski M., Czub-Swierczek M., Markowska J., Szyfter K. Bleomicin-induced DNA damage and its removal in lymphocytes of breast cancer patients studied by comet assay. Mutat Res 1997, 385:223-233.
39. Estevanato L., Cintra D., Baldini N., Portilho F., Barbosa L., Martins O., et al. Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system. Int J Nanomedicine 2011, 6:1709-1717.
40. Thrall M.A., Baker D.C., Campbell T.W., DeNicola D., Fettman M.J., Lassen E.D., et al. Hematologia e Bioquímica Clínica Veterinária 2007, Editora Roca, São Paulo, Brazil. 1st ed.
41. Everds N.E. Hematology of the laboratory mouse. The mouse in biomedical research: normative biology, husbandry, and models 2007, 133-170. Elsevier, San Diego, California, USA. J.G. Fox, S.W. Barthold, M.T. Davisson, C.E. Newcomer, F.W. Quimby, A.L. Smith (Eds.).
42. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett 2008, 266:53-59.
43. Hunter K.W. Mouse models of cancer: does the strain matter?. Nat Rev Cancer 2012, 12:144-149.
44. Bast A., Haenen G.R. Ten misconceptions about antioxidants. Trends Pharmacol Sci 2013, 34:430-436.
45. Parsons K.K., Maeda N., Yamauchi M., Banes A.J., Koller B.H. Ascorbic acid-independent synthesis of collagen in mice. Am J Physiol Endocrinol Metab 2006, 290:E1131-E1139.
46. Danesi R., Fogli S., Gennari A., Conte P., Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002, 41:431-444.
47. Hande K.R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998, 1400:173-184.
48. Fadillioglu E., Oztas E., Erdogan H., Yagmurca M., Sogut S., Ucar M., et al. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 2004, 24:47-52.
49. Quimby F.W., Luong R.H. Clinical chemistry of the laboratory mouse. The mouse in biomedical research: normative biology, husbandry, and models 2007, 171-216. Elsevier, San Diego, California, USA. J.G. Fox, S.W. Barthold, M.T. Davisson, C.E. Newcomer, F.W. Quimby, A.L. Smith (Eds.).
50. Sutherland R.J. Biochemical evaluation of the hepatobiliary system in dogs and cats. Vet Clin North Am Small Anim Pract 1989, 19:899-927.
51. Miras-Parra F.J., Parra-Ruiz J., Gómez-Morales M., Gómez-Jiménez F.J., de la Higuera-Torres-Puchol J. Inflammatory pseudotumor of lymph nodes with focal infiltration in liver and spleen. Dig Dis Sci 2003, 48:2003-2004.
52. Faraj W., Ajouz H., Mukherji D., Kealy G., Shamseddine A., Khalife M. Inflammatory pseudo-tumor of the liver: a rare pathological entity. World J Surg Oncol 2011, 9:5.
53. Li L., Cerilli L.A., Wick M.R. Inflammatory pseudotumor (myofibroblastic tumor) of the heart. Ann Diagn Pathol 2002, 6:116-121.
54. Goldberg D.M. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980, 12:1-58.
55. Lushchak V.I. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids 2012, 2012:1-26.
56. Kelly S.J., Lambie N.K., Singh H.P. Inflammatory myofibroblastic tumor of the left ventricle in an older adult. Ann Thorac Surg 2003, 75:1971-1973.
57. Schunke K.J., Coyle L., Merrill G.F., Denhardt D.T. Acetaminophen attenuates doxorubicin-induced cardiac fibrosis via osteopontin and GATA4 regulation: Reduction of oxidant levels. J Cell Physiol 2013, 228:2006-2014.
58. Heaney M.L., Gardner J.R., Karasavvas N., Golde D.W., Scheinberg D.A., Smith E.A., et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008, 68:8031-8038.
59. Berthiaume J.M., Oliveira P.J., Fariss M.W., Wallace K.B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 2005, 5:257-267.
60. Carrillo C., Cavia MdM., Alonso-Torre S.R. Antitumor effect of oleic acid; mechanisms of action: a review. Nutr Hosp 2012, 27:1860-1865.
61. Crowe F.L., Allen N.E., Appleby P.N., Overvad K., Aardestrup I.V., Johnsen N.F., et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2008, 88:1353-1363.
62. Bartsch H., Nair J., Owen R.W. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis 1999, 20:2209-2218.